{
    "clinical_study": {
        "@rank": "89117", 
        "acronym": "AAA", 
        "arm_group": [
            {
                "arm_group_label": "ACZ885", 
                "arm_group_type": "Experimental", 
                "description": "Active ACZ885"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo to match ACZ885"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to assess the safety, tolerability and efficacy of ACZ885 on\n      aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA). The purpose of the\n      study is to provide data to enable decisions regarding the further development of ACZ885 for\n      subjects with abdominal aortic aneurysms. The design of this study addresses the primary\n      objective of evaluating the change in aneurysmal size in subjects with AAA as a result of\n      treatment with ACZ885."
        }, 
        "brief_title": "ACZ885 for the Treatment of Abdominal Aortic Aneurysm", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Abdominal Aortic Aneurysm (AAA)", 
        "condition_browse": {
            "mesh_term": [
                "Aneurysm", 
                "Aortic Aneurysm", 
                "Aortic Aneurysm, Abdominal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female subjects age \u226545 years of age\n\n          2. Infrarenal abdominal aortic aneurysm with maximum diameter: for men \u226540mm and \u226450mm;\n             for women \u226538mm and \u226448mm.\n\n          3. On a stable medical regimen for at least 2 weeks prior to dosing, per investigator\n             assessment.\n\n          4. Have an evaluable ultrasound image at screening for the quantitative determination of\n             the AAA size, per imaging core lab assessment.\n\n          5. At screening, vital signs should be within the following ranges: (a) oral body\n             temperature between 35.0-37.5\u00b0C; (b) systolic blood pressure, 90-170 mm Hg; (c)\n             diastolic blood pressure, 50-100 mm Hg; (d) pulse rate, 40 - 100 bpm.\n\n        Exclusion Criteria:\n\n          1. Use of other investigational drugs at the time of enrollment, or within 5 half-lives\n             of enrollment.\n\n          2. Known diabetes by medical history, an HbA1c of \u22656.5% at screening, or on an active\n             diabetic medical regimen.\n\n          3. History of malignancy of any organ system other than localized basal cell carcinoma\n             of the skin, treated or untreated, within the past 5 years.\n\n          4. Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant, unless they are using effective methods of contraception during\n             dosing and 30-day follow up period of the study.\n\n          5. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial\n             dosing, or longer if required by local regulation.\n\n          6. Subjects on the following medications:  (a) Chronic systemic steroid treatment or\n             other systemic immunosuppression; (b) Any biologic drugs targeting the immune system,\n             along with a history of any previous use of such drugs.\n\n          7. Presence of a non-healing wound or infection, including active urinary tract\n             infections, or any recent process requiring significant tissue healing per\n             investigator assessment.\n\n          8. Significant illness which has not resolved within four (4) weeks prior to initial\n             dosing or with a life expectancy less than 2 years.\n\n          9. Any of the following concomitant hepatic or renal conditions or diseases: (a)\n             Nephrotic syndrome, or eGFR less than 30 mL/min/1.73 m2 per CRCL formula; (b) Prior\n             organ transplant requiring immunosuppressive therapy; (c) Known active or recurrent\n             hepatic disorder.\n\n         10. Previous infra-renal aortic surgery\n\n         11. Planned major surgery\n\n         12. Known aortic dissection\n\n         13. Subjects with eligible AAA diameter, but with known slow growth (<2mm/year) or known\n             stable AAA size over the prior one year of surveillance per investigator assessment.\n\n         14. Subjects should exhibit no signs of clinically concerning unstable acceleration of\n             AAA size or growth rate at the time of enrollment per investigator assessment.\n\n         15. Known or suspected inherited connective tissue disorders (e.g., Marfan or Vascular\n             Ehlers Danlos syndrome).\n\n         16. Recently unstable clinically significant cardiac disease within 3 months of\n             screening, including but not limited to, unstable angina, acute myocardial\n             infarction, and congestive heart failure (NYHA class IV).\n\n         17. Uncontrolled or refractory hypertension per Investigator determination.\n\n         18. Live vaccinations within 3 months prior to randomization, or live vaccinations\n             planned during the study.\n\n         19. History of untreated tuberculosis infection or evidence of active tuberculosis (TB)\n             infection.\n\n         20. History of multiple and recurring allergies or allergy to the investigational\n             compound/compound class being used in this study.\n\n         21. History of immunodeficiency diseases, including a positive HIV (ELISA and Western\n             blot) test result.\n\n         22. A positive Hepatitis B surface antigen or Hepatitis C test result whether at\n             screening or historically.\n\n         23. For USA sites utilizing CT angiograms, subjects with a history of a previous reaction\n             to contrast agent, a known sensitivity to iodine and known allergies (e.g, shellfish\n             allergy), or other hypersensitivities to contrast agents.\n\n         24. Underlying immune disorders, autoimmunity or immunodeficiency.\n\n         25. History of drug or alcohol abuse within the 12 months prior to dosing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007252", 
            "org_study_id": "CACZ885X2201", 
            "secondary_id": "2013-002088-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "ACZ885", 
                "description": "Monthly doses of ACZ885 subcutaneous (s.c.)", 
                "intervention_name": "ACZ885", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Monthly doses of placebo to match  ACZ885 s.c", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Abdominal Aortic Aneurysm", 
            "AAA", 
            "IL-1b", 
            "Abdominal ultrasound"
        ], 
        "lastchanged_date": "December 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22903"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aalborg", 
                        "country": "Denmark", 
                        "zip": "DK-9100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "DK-2100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kolding", 
                        "country": "Denmark"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odense C", 
                        "country": "Denmark", 
                        "zip": "DK-5000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eindhoven", 
                        "country": "Netherlands", 
                        "zip": "5602ZA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3508 GA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goteborg", 
                        "country": "Sweden"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orebro", 
                        "country": "Sweden", 
                        "zip": "701 16"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "171 76"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Denmark", 
                "Netherlands", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study of Subcutaneous ACZ885 for the Treatment of Abdominal Aortic Aneurysm", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Growth rate of AAA will be measured from ultrasound assessment.", 
            "measure": "Change from baseline in Abdominal Aortic Aneurysm (AAA) size per year", 
            "safety_issue": "No", 
            "time_frame": "Baseline, end of study (13 month)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007252"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients with adverse events, serious adverse events and death to assess safety and tolerability of ACZ885", 
            "safety_issue": "Yes", 
            "time_frame": "End of study (13 months)"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}